Use of Haploid Model of Candida albicans to Uncover Mechanism of Action of a Novel Antifungal Agent

Thuyen Truong, Tanujaa Suriyanarayanan, Guisheng Zeng, Thuc Duy Le, Lin Liu, Jiuyong Li, Tong Cao, Yue Wang, Chaminda Jayampath SeneviratneFrontiers in Cellular and Infection Microbiology 2018 · DOI

TL;DR

This study leverages a newly developed haploid Candida albicans model to elucidate the mechanism of action of a novel antifungal agent, SM21. The research reveals that SM21 targets fungal mitochondria, leading to their dysfunction, and also identifies a link between amino acid supplementation and resistance to SM21.

What Problem Does This Paper Address?

Candida albicans is a major human fungal pathogen responsible for serious infections, yet the development of new antifungal drugs has been hampered by limited options and the complexity of studying this organism. C. albicans is naturally diploid, meaning it has two copies of each gene, which makes it difficult to study gene function and generate resistant mutants. Traditional genetic approaches often require knocking out both copies of a gene to observe a phenotype, a process that is time-consuming and inefficient. This diploid nature also complicates the study of drug resistance mechanisms. The recent discovery of haploid C. albicans strains offers a powerful new tool to overcome these challenges, enabling simpler genetic manipulation and more efficient generation of resistant mutants. This paper aims to demonstrate the utility of this haploid model in uncovering the mechanism of action of a promising new antifungal agent, SM21, and to understand how C. albicans develops resistance to it.

Methods

The researchers employed a multi-pronged approach:

  • Transcriptomics (RNA-Seq): They performed comprehensive RNA sequencing on the haploid C. albicans strain GZY803, both with and without SM21 treatment, to identify genes whose expression levels changed significantly. This was done at early time points (1 and 4 hours) to capture immediate responses.
  • Mitochondrial Assays: To investigate the impact of SM21 on mitochondria, they conducted several experiments:
  • Mitochondrial Structure Visualization: Using fluorescent microscopy with MitoTracker Red, they visualized the physical structure of mitochondria in treated and untreated cells, including a known mitochondrial mutant (dnm1Δ) as a control.
  • ATP Production Measurement: They quantified ATP generation using a microbial cell viability assay, as ATP is crucial for cellular energy.
  • Reactive Oxygen Species (ROS) Measurement: They assessed ROS levels using MitoSOX staining, as mitochondria are a major source of ROS.
  • Total Antioxidant Potential Measurement: They measured the overall antioxidant capacity of the cells.
  • Generation of Resistant Mutants: They exposed the haploid GZY803 strain to SM21 repeatedly to select for spontaneous resistant mutants. Three such resistant colonies (S3, S5, S6) were isolated and characterized.
  • Ploidy Analysis: Flow cytometry was used to confirm that the isolated resistant strains remained haploid.
  • Differential Gene Expression Analysis: They compared the transcriptomic profiles of the resistant strains to the parent strain, both with and without SM21 treatment, to identify genes and pathways associated with resistance.
  • Functional Annotation (Gene Ontology): They used bioinformatics tools (Cytoscape, BINGO) to analyze the biological processes and cellular pathways affected by SM21 treatment and by the development of resistance.
  • Susceptibility Testing: Minimum Inhibitory Concentration (MIC) assays were performed to determine the sensitivity of various strains to SM21 and other antifungal drugs.
  • Peptone Supplementation Experiments: To test their hypothesis about amino acid supplementation and resistance, they supplemented growth media with peptone and re-evaluated the susceptibility of strains to SM21.

Datasets

  • Gene Expression Data: RNA-Seq data from C. albicans GZY803 and its SM21-resistant derivatives (S3, S5, S6) under SM21 treatment and control conditions. This data has been deposited in NCBI's Gene Expression Omnibus (GEO Series accession number GSE104900).
  • Control Strains: The study utilized the haploid strain GZY803 as the parent strain and the diploid strain SC5314 as a wild-type control. A known mitochondrial mutant, dnm1Δ, was also used as a positive control for mitochondrial defects.

Key Insights and Ideas

  • Haploid Model Powerhouse: The study strongly validates the utility of the haploid C. albicans model for drug discovery. It demonstrates how this simpler genetic background facilitates rapid identification of drug targets and resistance mechanisms, which would be significantly more challenging in diploid strains.
  • Mitochondria as the Achilles' Heel: SM21's primary target appears to be the fungal mitochondria. The drug disrupts mitochondrial structure, impairs ATP production, increases ROS levels, and reduces antioxidant capacity. This broad mitochondrial dysfunction is likely the key to its fungicidal activity.
  • Resistance Linked to Metabolism: The SM21-resistant strains showed altered gene expression patterns, particularly an upregulation of genes involved in protein and peptide metabolism and secreted aspartate proteases (SAPs). This suggests that the fungus attempts to compensate for mitochondrial stress or nutrient deprivation by enhancing its ability to break down and utilize external nutrients.
  • Amino Acid Supplementation as a Resistance Factor: The research provides compelling evidence that increased availability of amino acids (via peptone supplementation) can confer resistance to SM21. This is a crucial insight, as it suggests that host nutritional status or specific dietary interventions could influence the efficacy of SM21 treatment.

Key Results

  • SM21 treatment of haploid C. albicans GZY803 led to significant changes in gene expression, with a notable downregulation of genes involved in mitochondrial ATP-coupled electron transport and respiration.
  • Mitochondrial structure visualization confirmed defects in SM21-treated cells, and ATP production was significantly reduced.
  • SM21 treatment also increased ROS levels and decreased total antioxidant capacity in both haploid and diploid C. albicans strains.
  • Three SM21-resistant haploid strains (S3, S5, S6) were generated, exhibiting a 4-fold increase in SM21 MIC compared to the parent strain. These resistant strains showed similar susceptibility to other tested antifungals.
  • Resistant strains displayed enhanced expression of genes related to protein and peptide metabolism and secreted aspartate proteases (SAPs).
  • Supplementing growth media with peptone increased the SM21 MIC of both wild-type and resistant strains, indicating a role for amino acid availability in resistance.

Limitations and Future Work

  • Mechanism of SAP Regulation: While the study observed increased SAP activity in resistant strains, the precise transcriptional mechanisms regulating SAP expression in response to SM21 and amino acid supplementation remain to be uncovered.
  • Targeted Mitochondrial Protein Studies: The authors suggest that further experiments targeting specific mitochondrial proteins are warranted to obtain more conclusive evidence for SM21's mechanism of action.
  • In Vivo Efficacy in Resistant Strains: While SM21 showed promising in vivo activity in the abstract, the paper doesn't detail its efficacy against SM21-resistant strains in vivo. Future work could explore this.
  • Broader Resistance Mechanisms: The study focused on a few key resistance pathways. Further investigation into other potential resistance mechanisms beyond amino acid supplementation and SAP activity could be beneficial.
  • Clinical Translation: While the findings are promising for developing SM21 as a novel antifungal, further clinical trials and studies on its long-term efficacy and safety profile would be necessary.

Summary updated

Abstract

Antifungal agents for the treatment of <i>Candida albicans</i> infections are limited. We recently discovered a novel antifungal small molecule, SM21, with promising <i>in vivo</i> activity. Herein, we employed the newly developed <i>C. albicans</i> haploid toolbox to uncover the mechanism of action of SM21. Comprehensive RNA-Seq analyses of the haploid susceptible GZY803 strain revealed significant gene expression changes related to mitochondria when exposed to SM21. Mitochondrial structure visualization and measurement of ATP generation, reactive oxygen species (ROS) levels, and the antioxidant potential of SM21-treated and untreated GZY803, mitochondrial structure defective haploid mutant (<i>dnm1</i>Δ), and wild-type diploid SC5314 strains confirmed defects in mitochondria. Exploiting the advantage of <i>C. albicans</i> haploids as a single ploidy model, we further exposed GZY803 to repetitive treatments of SM21 in order to generate resistant mutants. Three colonies designated S3, S5 and S6, which displayed resistance to SM21, were isolated. All resistant strains exhibited enhanced transcriptomic responses for peptide and protein metabolism and secreted aspartate proteases (SAPs) activity under SM21 treatment compared to the parent strain GZY803. Consistently, supplementing the resistant strains, GZY803, and SC5314 with peptone, a form of digested peptides, decreased susceptibility to SM21. The present study demonstrates the usefulness of haploid <i>C. albicans</i> model in antifungal drug discovery. The findings will be invaluable to develop SM21 as a novel antifungal agent, which will benefit millions of patients suffering from <i>Candida</i> infections.
BibTeX
@inproceedings{truong2018use,
  author = {Thuyen Truong and Tanujaa Suriyanarayanan and Guisheng Zeng and Thuc Duy Le and Lin Liu and Jiuyong Li and Tong Cao and Yue Wang and Chaminda Jayampath Seneviratne},
  title = {{Use of Haploid Model of Candida albicans to Uncover Mechanism of Action of a Novel Antifungal Agent}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2018},
  doi = {10.3389/fcimb.2018.00164},
}
Figure